BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline
Retatrutide Phase 3 Data: What TRIUMPH-4 and TRIUMPH-1-OA Mean for the Triple-Agonist GLP-1 Pipeline
Phase 3 trials of Eli Lilly's investigational triple agonist retatrutide, presented at ACR Convergence 2026 and simultaneously published in the New England Journal of Medicine, show significant reductions in knee osteoarthritis pain alongside substantial weight loss. With a biologics licence application targeted for Q1 2027, the compound represents the most advanced triple-agonist peptide in the obesity and musculoskeletal pipeline.
11 Nov 2026
Research Pipeline
BPC-157: Evidence Base, Regulatory Status, and Procurement Considerations for UK Research Laboratories
BPC-157 is the most prominently discussed of the six peptides covered by the October 2026 HHS enforcement discretion policy, yet two formal systematic reviews published this year conclude that human evidence remains very low quality. This briefing summarises the current clinical and preclinical evidence, US and UK regulatory status, and what procurement teams should verify before sourcing the compound.
07 Nov 2026
Research Pipeline
Thymosin Alpha-1: Mechanism, Clinical Evidence, and Regulatory Status for UK Research Procurement
Thymosin alpha-1 (Tα1) is a 28-amino-acid immunomodulatory peptide approved as Zadaxin in more than 35 countries — but not by the FDA, MHRA, or EMA. A 2026 scoping review, a 2025 phase 3 sepsis trial, and active vaccine-adjuvant research make it one of the better-evidenced non-approved peptides in circulation. This briefing maps the mechanism, evidence base, regulatory standing, and procurement considerations for UK laboratories.
03 Nov 2026
Research Pipeline
GHK-Cu: Evidence Base, Regulatory Status, and Procurement Considerations for UK Research Laboratories
GHK-Cu, the naturally occurring copper tripeptide, sits at a regulatory inflection point: removed from FDA Category 2 in April 2026, scheduled for a second PCAC review before the end of February 2027, and under active Phase 2 clinical investigation for wound healing. A comprehensive 2026 review in Pharmaceutics confirms robust preclinical signal but sparse clinical evidence — a distinction that matters for procurement and compliance decisions at UK research labs.
01 Nov 2026
Research Pipeline
Retatrutide Beats Semaglutide 2 mg on Every Primary Endpoint in First Phase 3 Head-to-Head Trial: What the TRANSCEND-T2D-2 Results Mean for Research Procurement
Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist retatrutide produced more than double the weight loss of Ozempic's highest approved dose at 80 weeks in adults with type 2 diabetes, according to topline Phase 3 TRANSCEND-T2D-2 data released on 28 October 2026. The readout — the sixth consecutive positive Phase 3 trial for the compound — solidifies retatrutide's clinical profile and accelerates the timeline toward a potential regulatory filing, with direct implications for how research…
30 Oct 2026
Research Pipeline
MOTS-c: What the July 2026 PCAC Vote and the October Interim Policy Mean for Research Procurement
The FDA's Pharmacy Compounding Advisory Committee voted 7–5 in July 2026 to recommend MOTS-c for the 503A Bulks List, overruling its own staff. Three months on, formal rulemaking has not begun and MOTS-c remains unlisted. This briefing sets out what MOTS-c is, where the evidence stands, and what the unresolved regulatory picture means for UK research procurement.
28 Oct 2026
Research Pipeline
Beyond the GLP-1 Duopoly: Three October Developments That Signal a Broadening Obesity Pipeline
A Phase 2b trial win for Zealand Pharma's amylin analogue petrelintide, a £1.2 billion AI-protein partnership with Generate Biomedicines, and Novo Nordisk's €1.165 billion bet on long-acting PharmaShell technology collectively point to an obesity therapeutics landscape that is moving deliberately beyond weekly GLP-1 injections.
22 Oct 2026
Research Pipeline
Thymosin Alpha-1: What 35 Countries of Clinical Use and a Lopsided PCAC Vote Mean for Research Access in 2026
Thymosin alpha-1 (Tα1) holds approved-drug status in more than 35 countries for hepatitis B and immune support in oncology, yet its US regulatory position remains unresolved — the FDA's own advisory committee voted 4–17 against 503A compounding inclusion in December 2024. This briefing maps the clinical evidence, the mechanism, and what the peptide's unusual regulatory position means for UK research procurement today.
07 Oct 2026
Research Pipeline
Viking Therapeutics Initiates Oral Maintenance Dosing Study for VK2735: What the GLP-1/GIP Dual Agonist's Two-Part Programme Tells Researchers About the Weight-Regain Problem
Viking Therapeutics has launched Part 2 of its VK2735 maintenance dosing study, this time focusing on oral tablet regimens following subcutaneous induction. Part 1 top-line data, reported on 22 September, showed less-frequent injections preserved up to 97% of prior weight loss — setting a high benchmark for the oral arm now beginning enrolment.
06 Oct 2026
Research Pipeline
GHK-Cu: What a Fresh Diabetic Wound Study and a Recruiting Phase 2 Trial Mean for the Copper Peptide's Research Standing
A new Carbohydrate Polymers study and a Phase 2 wound-healing trial currently recruiting signal renewed preclinical and early clinical momentum for GHK-Cu. Here is what laboratory procurement teams need to know about the peptide's mechanism, evidence base, and regulatory position in the UK and US.
03 Oct 2026
Research Pipeline
EASD Milan 2026: Three Datasets That Reframe the Next Wave of Peptide-Based Obesity Treatments
The 62nd Annual Meeting of the European Association for the Study of Diabetes closed in Milan on 2 October 2026 with three datasets of direct relevance to peptide researchers and procurement professionals: Phase 3 efficacy data for olatorepatide, real-world switching evidence for oral semaglutide, and Phase 2 muscle-preservation results for trevogrumab combined with semaglutide.
02 Oct 2026
Research Pipeline
Kailera Therapeutics and the Ribupatide Franchise: Inside the GLP-1 Challenger That Went Public With $719 Million and a Four-Asset Obesity Pipeline
Kailera Therapeutics, the Waltham-based clinical-stage company that raised $719 million in its April 2026 IPO, is running four simultaneous GLP-1 programmes — injectable and oral ribupatide, a small-molecule oral agonist, and a tri-agonist — to challenge Novo Nordisk and Eli Lilly. This briefing examines the ribupatide evidence base, the Hengrui partnership underpinning global access, upcoming data milestones, and what the strategy means for the research-procurement community.
29 Sep 2026